BTG plc (LON:BTG)‘s stock had its “buy” rating reissued by equities researchers at Deutsche Bank AG in a research report issued on Friday, MarketBeat.com reports. They presently have a GBX 775 ($10.19) target price on the stock. Deutsche Bank AG’s price objective would indicate a potential upside of 9.93% from the company’s current price.

Other equities research analysts have also recently issued research reports about the company. Numis Securities Ltd reiterated a “buy” rating and issued a GBX 900 ($11.83) price objective on shares of BTG plc in a report on Thursday, June 29th. Stifel Nicolaus reiterated a “buy” rating and issued a GBX 800 ($10.52) price objective on shares of BTG plc in a report on Wednesday, August 30th. Peel Hunt reiterated a “hold” rating and issued a GBX 680 ($8.94) price objective on shares of BTG plc in a report on Wednesday, September 20th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of BTG plc in a report on Friday, October 6th. Finally, Shore Capital restated a “not rated” rating on shares of BTG plc in a research note on Thursday, July 13th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of GBX 780.33 ($10.26).

BTG plc (LON:BTG) traded down 0.35% during midday trading on Friday, hitting GBX 705.00. The stock had a trading volume of 369,450 shares. BTG plc has a 12 month low of GBX 528.36 and a 12 month high of GBX 738.50. The firm’s 50-day moving average price is GBX 687.70 and its 200 day moving average price is GBX 667.58. The company’s market cap is GBX 2.71 billion.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/14/btg-plc-btg-receives-buy-rating-from-deutsche-bank-ag-2.html.

About BTG plc

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Analyst Recommendations for BTG plc (LON:BTG)

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.